Gritstone Bio Current Ratio 2017-2022 | GRTS
Gritstone Bio current ratio from 2017 to 2022. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
| Gritstone Bio Current Ratio Historical Data |
| Date |
Current Assets |
Current Liabilities |
Current Ratio |
| 2022-03-31 |
$0.19B |
$0.03B |
5.65 |
| 2021-12-31 |
$0.22B |
$0.04B |
5.52 |
| 2021-09-30 |
$0.22B |
$0.04B |
6.01 |
| 2021-06-30 |
$0.18B |
$0.02B |
8.25 |
| 2021-03-31 |
$0.20B |
$0.02B |
9.30 |
| 2020-12-31 |
$0.18B |
$0.03B |
6.50 |
| 2020-09-30 |
$0.07B |
$0.02B |
3.35 |
| 2020-06-30 |
$0.09B |
$0.02B |
4.93 |
| 2020-03-31 |
$0.11B |
$0.02B |
6.09 |
| 2019-12-31 |
$0.13B |
$0.02B |
6.73 |
| 2019-09-30 |
$0.16B |
$0.02B |
6.76 |
| 2019-06-30 |
$0.19B |
$0.02B |
10.22 |
| 2019-03-31 |
$0.14B |
$0.01B |
9.57 |
| 2018-12-31 |
$0.16B |
$0.02B |
10.43 |
| 2018-09-30 |
$0.08B |
$0.01B |
6.13 |
| 2018-06-30 |
$0.00B |
|
0.00 |
| 2018-03-31 |
$0.00B |
|
0.00 |
| 2017-12-31 |
$0.00B |
|
0.00 |
| 2017-09-30 |
$0.00B |
|
0.00 |
| 2016-12-31 |
$0.04B |
$0.00B |
15.39 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.141B |
$0.048B |
|
Gritstone Oncology is developing tumor-specific cancer immunotherapies to fight multiple cancer types. The company has built its tumor-specific immunotherapy approach on two key pillars - first, a proprietary machine learning-based platform, Gritstone EDGE(TM), which provides a powerful ability to predict from a routine tumor biopsy the tumor-specific neoantigens, or TSNA, that are presented on a patient?s tumor cells; and second, the ability to develop and manufacture potent immunotherapies utilizing patients? TSNA to drive the patient?s immune system to attack and destroy tumors.
|
